A Streamlit app for predicting drug-target binding affinity using a trained CNN model. Input SMILES strings and protein sequences for fast and accurate predictions.

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue ...

Buoyed by the breakthrough technologies and methodologies that have enabled earlier intervention, Alzheimer’s drug developers ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug design. Hassabis, a Nobel laureate for his work on AlphaFold, believes AI ...

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic ...

In a study published in Angewandte Chemie International Edition, a research team integrated activity-based protein profiling ...